Clinical Trial Update: Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab and tremelimumab in combination with Y-90 SIRT for intermediate-stage hepatocellular carcinoma is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)
• Y-90 SIRT (yttrium-90 selective internal radiation therapy)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Hepatocellular Carcinoma Non-resectable, HCC | Phase 2 | Status: RECRUITING